ctDNA Positivity Appears to Predict Risk of Recurrence, Benefit from Adjuvant Chemotherapy in Resectable CRCJanuary 19th 2023
An expert from Natera discusses ctDNA’s predictive and prognostic value in resectable colorectal cancer based on data from the GALAXY cohort of the CIRCULATE-JAPAN platform study.
Further Clinical Research Will ‘Push the Needle Forward’ for and Encourage Clinical Adoption ctDNA in Colorectal CancerJanuary 17th 2023
An expert from Natera describes where future research needs to be focused for circulating tumor DNA testing in patients with colorectal cancer following the CIRCULATE-Japan study.
Expert Describes the Role ctDNA Testing May Play in the Multidisciplinary Care of Colorectal CancerJanuary 16th 2023
An expert from Natera shares multidisciplinary takeaways from the GALAXY cohort of the CIRCULATE-Japan study, assessing circulating tumor DNA as a prognostic biomarker for resectable colorectal cancer.